Seres Therapeutics Inc (MCRB) 13F Holders & Ownership Data (38 Funds, Q2 2026)

Seres Therapeutics (ticker: MCRB) released its Q2 2026 earnings on August 5, 2026, covering the period ending June 30, 2026, and provided an operational update. The press release with the details is attached as Exhibit 99.1 in this 8-K. The filing itself doesn't include specific numbers, so you'd need to check the press release for the actual results.

Seres Therapeutics (ticker: MCRB) disclosed on July 31, 2026 that it signed a lease amendment and termination agreement with its Cambridge, Massachusetts landlord, BMR-Sidney Research Campus LLC. The company will surrender about 21,295 square feet of its 200 Sidney Street space, and the lease on the remaining 47,341 square feet will now expire on December 31, 2026 instead of January 13, 2031. In exchange, Seres will increase a letter of credit by roughly $2.2 million, make a deferred $3.85 million payment by January 4, 2027, and issue 103,520 common shares (valued at about $500,000 based on the $4.83 closing price) to the landlord. Management says the deal reduces ongoing annual facilities costs and largely eliminates its primary restoration obligations.

No AI summary for this filing type

Seres Therapeutics (ticker: MCRB) held its annual shareholder meeting on July 8, 2026, after an earlier adjournment due to lack of a quorum. Shareholders voted to amend the company's 2025 Incentive Award Plan, increasing the share pool by 900,000 shares.